Tyrosine-protein kinase JAK1 antibody
Principal name
Tyrosine-protein kinase JAK1 antibody
Alternative names for Tyrosine-protein kinase JAK1 antibody
Janus kinase 1, JAK-1, JAK1A, JAK1B
Gene ID
3716 (JAK1)
Ncbi ID
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Paraffin Sections (P), Immunocytochemistry/Immunofluorescence (ICC/IF)
Background of Tyrosine-protein kinase JAK1 antibody
JAK1 (Janus kinase 1) belongs to the family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK1. JAK1 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to cis elements upstream of target gene promoters to regulate transcription. Upon ligand binding, JAK1 undergoes tyrosine phosphorylation and catalytic activation in an interdependent manner. Phosphorylation of tyrosine residues at positions 1022 and 1023 is believed to function in the activation
of catalytic events. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies.
General readings
1. Sutherland JM et al. Suppressor of cytokine signaling 4 (SOCS4): moderator of ovarian primordial follicle activation. J Cell Physiol 227:1188-98 (2012). IHC-P ; Mouse . PubMed: 21604262
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using JAK1 Antibody (Phospho-Tyr1022) Cat.-No AP02433PU.
Western blot analysis of extract from thyroid cancer cell line Bph cells, using JAK1 Antibody (Phospho-Tyr1022) Cat.-No AP02433PU.
Western blot analysis of extracts from HT29 cells untreated or treated with UV using JAK1 Antibody (Phospho-Tyr1022) Cat.-No AP02433PU.
Figure 1. Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using JAK1 antibody AP02649PU.
Figure 2. Western blot analysis of extracts from MCF7 cells using JAK1 antibody AP02649PU.
Immunohistochemistry (IHC) analysis of JAK1 pTyr1022 antibody (Cat.-No.: AP01620PU-N) in paraffin-embedded human breast carcinoma tissue.
Immunohistochemistry with AP20955PU-N antibody in paraffin-embedded human breast carcinoma tissue.
Immunohistochemistry (IHC) analyzes of JAK1 pAb in paraffin-embedded human lung adenocarcinoma tissue.
Immunohistochemical analysis of JAK1 (pY1022) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Western blot analysis of JAK1 (pY1022) expression in Ramos (A); Jurkat (B); L929 (C); PC12 (D) whole cell lysates.
Immunohistochemical analysis of JAK1 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Immunofluorescent analysis of JAK1 staining in Jurkat cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Western blot analysis of JAK1 expression in Ramos (A); Jurkat (B); L929 (C); PC12 (D) whole cell lysates.
Western blot analysis of extracts from MCF7 cells using JAK1 antibody.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using JAK1 antibody.
Western blot analysis of extracts from A549, using JAK1 (Ab-1022) Antibody.The lane on the right is treated with the synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using JAK1 (Ab-1022) Antibody.The picture on the right is treated with the synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human brain tissue, using JAK1 antibody.The picture on the right is treated with the synthesized peptide.
Immunofluorescence analysis of HeLa cells, using JAK1 antibody.The picture on the right is treated with the synthesized peptide.
Predicted band size: 133 kDa . Positive control: NIH/3T3, HepG2, HT29 and MDA cells lysate. Recommended dilution: 1/ 500-1000. (Gel: 8%SDS-PAGE Lane1,2,3,4: NIH/3T3, HepG2, HT29 and MDA cells lysate Lysates: 30 ug per lane Primary antibody: 1/500 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 1 minute)
Predicted cell location: Endomembrane system; Peripheral membrane protein. Positive control: Human breast carcinoma tissue. Recommended dilution: 1/ 50-100 The image on the left is immunohistochemistry of paraffin-embedded human breast carcinoma tissue using JAK1 (Ab-1022) antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification: x200)
Western blot analysis of JAK1 expression in EGF treated MCF7 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Predicted band size: 133 kDa . Positive control: HT29 cells untreated or treated with UV lysate. Recommended dilution: 1/ 500-1000. (Gel: 8%SDS-PAGE Lane1: HT29 cells untreated with UV lysate Lane2: HT29 cells treated with UV lysate Lysates: 30 ug per lane Primary antibody: 1/500 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 1 minute)
Predicted cell location: Endomembrane system; Peripheral membrane protein. Positive control: Human breast carcinoma tissue. Recommended dilution: 1/ 50-100 The image on the left is immunohistochemistry of paraffin-embedded human breast carcinoma tissue using JAK1 (Phospho-Tyr1022) antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Western blot analysis of extracts from A549 cells, using JAK1 (Phospho-Tyr1022) antibody.The lane on the right is treated with the synthesized peptide.
Western blot analysis of extracts from 3T3 cells (Lane 2), using JAK1 (Phospho-Tyr1022) Antibody. The lane on the left is treated with synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using JAK1 (Phospho-Tyr1022) antibody.The picture on the right is treated with the synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using JAK1 (phospho-Tyr1022) antibody.
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP313878 | Tyrosine-protein kinase JAK1 |
||||
| Recombinant protein of human Janus kinase 1 (a protein tyrosine kinase) (JAK1) | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€788.00
|
|
| OriGene Technologies, Inc. | |||||
